Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model.
about
Interleukin-27: balancing protective and pathological immunityLeishmania major infection in humanized mice induces systemic infection and provokes a nonprotective human immune responseMurine models of acute leukemia: important tools in current pediatric leukemia research.Potential clinical application of interleukin-27 as an antitumor agent.The antitumor potential of Interleukin-27 in prostate cancer.IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner.Interleukin-27 rs153109 polymorphism and the risk of non-small-cell lung cancer in a Chinese population.IL-27 induces the expression of IDO and PD-L1 in human cancer cells.IL-27 Promotes Proliferation of Human Leukemic Cell Lines Through the MAPK/ERK Signaling Pathway and Suppresses Sensitivity to Chemotherapeutic Drugs.Proteomic analysis uncovers common effects of IFN-γ and IL-27 on the HLA class I antigen presentation machinery in human cancer cells.New directions in the basic and translational biology of interleukin-27.Pharmacogenomic considerations of xenograft mouse models of acute leukemia.MicroRNAs Involved in Anti-Tumour Immunity.Human TCRγδ+ T cells represent a novel target for IL-27 activity.Regulation and Immune Function of IL-27.Engraftment of low numbers of pediatric acute lymphoid and myeloid leukemias into NOD/SCID/IL2Rcγnull mice reflects individual leukemogenecity and highly correlates with clinical outcome.Association between IL-27 gene polymorphisms and risk of papillary thyroid carcinoma.Association of IL-27 rs153109 and rs17855750 Polymorphisms with Risk and Response to Therapy in Acute Lymphoblastic Leukemia.
P2860
Q26830400-581D226A-C50B-4185-8DBF-7844A4CFC447Q28481520-8738846A-543F-49DE-BBBF-6D4CBC473BCDQ33606018-5F980314-F1A1-480E-A0E0-9B1EAA9F6B8FQ34483131-45B76D0A-0B98-41F4-B016-6668D4E03395Q34786440-B0519314-E001-471D-94E4-67354E914E74Q35025256-BB86BF49-2F8B-42F2-B4BF-6918253EAFB5Q36627497-60B03285-6FA1-4E05-AD4F-6DDE3F414749Q36685395-232B0887-9D72-4BFD-BB63-F07BA797BA5FQ36861764-E9563557-57A5-413A-8F20-2AD28B302C8CQ37687254-EE1E5B62-E2BC-41A3-8106-1D9BD1D9BE95Q37969347-2822D4A1-B35B-40D7-9682-80E5FCAA31C5Q38061500-02767204-C9E6-419F-BDA6-EDFBFDBF5E82Q38088117-97FF6127-1778-40B4-9A2A-0560C1CA2AF5Q39606012-267C485D-91CE-4AE1-A994-9C6DD8E3CAA0Q40508641-E250FD9D-F30A-45AA-B605-B9E41BFCC9E8Q44558577-FB8E623A-C98D-4FC4-8F27-433FBEF4DC21Q51279715-D2471801-2313-4999-BE84-082E672F09A2Q53725899-B8C458BD-FDD7-4413-A3C2-F46433A512F7
P2860
Interleukin-27 inhibits pediatric B-acute lymphoblastic leukemia cell spreading in a preclinical model.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@en
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@nl
type
label
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@en
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@nl
prefLabel
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@en
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@nl
P2093
P2860
P356
P1433
P1476
Interleukin-27 inhibits pediat ...... eading in a preclinical model.
@en
P2093
C Sorrentino
E Di Carlo
E Seganfreddo
P2860
P2888
P304
P356
10.1038/LEU.2011.158
P577
2011-06-24T00:00:00Z